

REMARKS

Claims 1-10 are present in the above-captioned application and have been subjected to restriction under 35 U.S.C. §121 as follows:

- I. Claims 1-8, drawn to a liquid formulation of a therapeutic agent comprising: rapamycin in a pharmaceutically effective dosage; and one or more pharmaceutically acceptable solubility enhancers, classified in class 514, subclass 291.
- II. Claims 9-10, drawn to a method for treatment of vascular disease comprising the administration of a liquid formulation of rapamycin proximate the disease site, classified in class 514, subclass 291.

Applicants elect Group I, corresponding to Claims 1-8.

Docket No. CRD-5073USNP

Respectfully submitted,

/Carl J. Evens/

Carl J. Evens
Reg. No.: 33,874
Attorney for Applicant

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2518